Overview

ResMed occupies an unusual position on the Australian market. Although it is one of the most valuable healthcare names quoted in Sydney, it is a San Diego company that trades on the ASX through CHESS Depositary Interests, ten of which represent a single underlying share. It reports in US dollars, declares its Dividend in US dollars, and pays that dividend unfranked, since a United States company generates no Australian franking credits. For income investors accustomed to the fully franked payouts of the domestic banks, that distinction matters.

The Business in detail

ResMed sells the machinery of a chronic condition. Its core market is obstructive sleep apnoea, a disorder in which the airway repeatedly collapses during sleep, and its flagship products are continuous positive airway pressure devices, or CPAP machines, together with the masks and consumables that patients replace over the life of the device. That resupply cycle is the commercial heart of the company: once a patient is fitted, the recurring purchase of masks, cushions and filters produces an annuity-like Revenue stream that is rare for a hardware manufacturer.

Beyond the bedside device, the group has built a software business serving providers of out-of-hospital care, spanning home medical equipment, home health and senior living. This segment shifts part of the revenue base away from unit sales of hardware and toward recurring software subscriptions, giving the company two distinct engines.

Competitive position and peers

The global sleep and respiratory device market is a concentrated one, and ResMed's most direct listed comparator is Fisher and Paykel Healthcare (ASX: FPH), the New Zealand group whose respiratory humidification and hospital hardware overlap with parts of ResMed's range. The third large participant historically was Philips, whose Respironics unit was a principal competitor until a substantial product recall reshaped the market and directed share toward ResMed. Adjacent competition also comes from device makers pursuing alternative treatments, including implantable nerve-stimulation approaches from companies such as Inspire Medical Systems.

The dividend

ResMed goes ex-dividend on 19 August 2026. The declared amount is US$0.0655 per security, franked at zero per cent, and classified as a final dividend. Investors must hold the security before the ex-date to qualify. The unfranked status is a function of domicile rather than any weakness in the payout, and the currency exposure means the Australian-dollar value received will move with the exchange rate.

What shapes the Investment case

Two structural questions dominate discussion of ResMed. The first is the durability of the resupply model and the company's ability to keep converting new diagnoses into a growing installed base. The second, and more debated, is the arrival of GLP-1 weight-loss medicines and their potential effect on sleep apnoea, a condition strongly linked to obesity. Some observers argue these drugs threaten future device Demand by treating the underlying cause; others contend they will expand diagnosis and treatment overall. The resolution of that debate, more than any single quarter, is what long-term holders are weighing.